{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T08:35:19Z","timestamp":1793435719229,"version":"4.5.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["Omega-3 Fatty Acids for Treatment of Intestinal Failure Associated Liver Disease: A Translational Research Study, 2011-2014, CIHR 232514"],"award-info":[{"award-number":["Omega-3 Fatty Acids for Treatment of Intestinal Failure Associated Liver Disease: A Translational Research Study, 2011-2014, CIHR 232514"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010105","name":"\u00d6sterreichische Krebshilfe Tirol","doi-asserted-by":"publisher","award":["2009 - \\\"Hsp70 and HSPBP1 in carcinomas of the pancreas\\\""],"award-info":[{"award-number":["2009 - \\\"Hsp70 and HSPBP1 in carcinomas of the pancreas\\\""]}],"id":[{"id":"10.13039\/501100010105","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010105","name":"\u00d6sterreichische Krebshilfe Tirol","doi-asserted-by":"publisher","award":["2007 - \\\"DMBTI and cholangiocellular carcinomas\\\""],"award-info":[{"award-number":["2007 - \\\"DMBTI and cholangiocellular carcinomas\\\""]}],"id":[{"id":"10.13039\/501100010105","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["L313-B13"],"award-info":[{"award-number":["L313-B13"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008630","name":"Children's Health Research Institute","doi-asserted-by":"publisher","award":["2096"],"award-info":[{"award-number":["2096"]}],"id":[{"id":"10.13039\/100008630","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010322","name":"Stollery Children\u2019s Hospital Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009326","name":"Cancer Research Society","doi-asserted-by":"publisher","award":["von Willebrand factor gene expression in cancer cells"],"award-info":[{"award-number":["von Willebrand factor gene expression in cancer cells"]}],"id":[{"id":"10.13039\/100009326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.cct.2026.108493","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:34:48Z","timestamp":1790922888000},"page":"108493","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Survodutide for the treatment of obesity: Mechanistic rationale, clinical evidence, and remaining uncertainties"],"prefix":"10.1016","volume":"170","author":[{"given":"Consolato M.","family":"Sergi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2026.108493_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.108077","article-title":"IUPHAR review: from foe to friend: repurposing glucagon to treat obesity and type 2 diabetes","volume":"223","author":"Elmendorf","year":"2026","journal-title":"Pharmacol. Res."},{"issue":"2","key":"10.1016\/j.cct.2026.108493_bb0010","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1111\/dom.70263","article-title":"Baseline characteristics in the SYNCHRONIZE-2 randomized phase 3 trial of survodutide, a glucagon receptor\/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes","volume":"28","author":"Wharton","year":"2026","journal-title":"Diabetes Obes. Metab."},{"issue":"1","key":"10.1016\/j.cct.2026.108493_bb0015","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/dom.70196","article-title":"Survodutide for treatment of obesity: baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE-1)","volume":"28","author":"le Roux","year":"2026","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.cct.2026.108493_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2026.102326","article-title":"Survodutide acts through circumventricular organs in the brain and activates neuronal regions associated with appetite regulation","volume":"105","author":"Zimmermann","year":"2026","journal-title":"Mol. Metab."},{"issue":"1","key":"10.1016\/j.cct.2026.108493_bb0025","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/oby.24184","article-title":"Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE-1 and -2)","volume":"33","author":"Wharton","year":"2025","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.cct.2026.108493_bb0030","doi-asserted-by":"crossref","DOI":"10.1097\/CRD.0000000000001062","article-title":"Survodutide: a dual GLP-1\/glucagon agonist reshaping cardiometabolic care","author":"Arun","year":"2025","journal-title":"Cardiol. Rev."},{"issue":"3","key":"10.1016\/j.cct.2026.108493_bb0035","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1111\/dom.70407","article-title":"Operationalising disease modification in obesity trials: a blueprint based on the SYNCHRONIZE-1 survodutide study","volume":"28","author":"Wang","year":"2026","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.cct.2026.108493_bb0040","doi-asserted-by":"crossref","DOI":"10.1177\/20420188241227766","article-title":"Liver biopsy handling of metabolic-associated fatty liver disease (MAFLD): the Children\u2019s Hospital of Eastern Ontario grossing protocol","volume":"15","author":"Sergi","year":"2024","journal-title":"Ther. Adv. Endocrinol. Metab."},{"issue":"15","key":"10.1016\/j.cct.2026.108493_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25158462","article-title":"NAFLD (MASLD)\/NASH (MASH): does it bother to label at all? A comprehensive narrative review","volume":"25","author":"Sergi","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.cct.2026.108493_bb0050","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.jhep.2024.06.003","article-title":"Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon\/glucagon-like peptide-1 receptor dual agonist, in cirrhosis","volume":"81","author":"Lawitz","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cct.2026.108493_bb0055","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2020.00271","article-title":"How to conduct a Bayesian network meta-analysis","volume":"7","author":"Hu","year":"2020","journal-title":"Front. Vet. Sci."},{"issue":"11","key":"10.1016\/j.cct.2026.108493_bb0060","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1002\/oby.24360","article-title":"Efficacy and safety of GLP-1 receptor agonists, dual agonists, and Retatrutide for weight loss in adults with overweight or obesity: a Bayesian NMA","volume":"33","author":"Sinha","year":"2025","journal-title":"Obesity (Silver Spring)"},{"issue":"10401","key":"10.1016\/j.cct.2026.108493_bb0065","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","article-title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA","volume":"402","author":"Rosenstock","year":"2023","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.cct.2026.108493_bb0070","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1080\/14656566.2023.2181074","article-title":"Profile of tirzepatide in the management of type 2 diabetes mellitus: design, development, and place in therapy","volume":"24","author":"Naseralallah","year":"2023","journal-title":"Expert. Opin. Pharmacother."},{"issue":"1","key":"10.1016\/j.cct.2026.108493_bb0075","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s13300-020-00981-0","article-title":"The role of Tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of Type 2 diabetes: the SURPASS clinical trials","volume":"12","author":"Min","year":"2021","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.cct.2026.108493_bb0080","author":"Osei"},{"key":"10.1016\/j.cct.2026.108493_bb0085","article-title":"Long-term cancer risk in users of GLP-1 agonists in Denmark: a nationwide emulated trial","volume":"55","author":"Gamborg","year":"2025","journal-title":"Lancet Reg. Health Eur."},{"issue":"8","key":"10.1016\/j.cct.2026.108493_bb0090","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1111\/dom.16489","article-title":"GLP-1 receptor agonists and the risk for cancer: a meta-analysis of randomized controlled trials","volume":"27","author":"Silverii","year":"2025","journal-title":"Diabetes Obes. Metab."}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155171442600279X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155171442600279X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T08:18:08Z","timestamp":1793434688000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155171442600279X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":18,"alternative-id":["S155171442600279X"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2026.108493","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survodutide for the treatment of obesity: Mechanistic rationale, clinical evidence, and remaining uncertainties","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2026.108493","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108493"}}